

BÜHLMANN anti-MAG & -Ganglioside Autoantibody ELISA IVD tests – far over 80 References



BÜHLMANN GanglioCombi™

Civardi C et al., 2020: Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection. J Neurol Neurosurg Psychiatry **28 August, 2020**
DOI: [10.1136/jnnp-2020-324279](https://doi.org/10.1136/jnnp-2020-324279) PMID: **32859744**

Toscano G et al., 2020: Guillain-Barré Syndrome Associated with SARS-CoV-2 (Letter to the editor). NEJM; **April 27, 2020**
DOI: [10.1056/NEJMc2009191](https://doi.org/10.1056/NEJMc2009191)

Delmont E et al., 2019: Relevance of anti-HNK-1 Antibodies in the management of anti-MAG neuropathies. J Neurol; published online **14 May, 2019**
DOI: [10.1007/s00415-019-09367-0](https://doi.org/10.1007/s00415-019-09367-0)

Choi K-D et al., 2019: Characteristics of a single oculomotor nerve palsy associated with anti-GQ1b antibody. J Neurol **266**: 476-479
DOI: [10.1007/s00415-018-9161-8](https://doi.org/10.1007/s00415-018-9161-8)

Yoon L et al., 2019: Clinical characterization of anti-GQ1b antibody syndrome in Korean children. J Neuroimmunology **15(330)**: 170-173
DOI: [10.1016/j.jneuroim.2019.01.003](https://doi.org/10.1016/j.jneuroim.2019.01.003)

Lee S U et al., 2019: Anti-ganglioside antibody associated acute unilateral vestibulopathy. J Neurol **266(1)**: 250-252
DOI: [10.1007/s00415-018-9109-z](https://doi.org/10.1007/s00415-018-9109-z)

Sohn S Y and Kim J K, 2018: Neutropenia Following Intravenous Immunoglobulin Administration in a Patient with Multifocal Motor Neuropathy with Conduction Block. J Neurol Neurophysiol **8**: 409.
DOI: [10.4172/2155-9562.1000409](https://doi.org/10.4172/2155-9562.1000409)

Franciotta D et al., 2018: Anti-ganglioside antibodies: experience from the Italian Association of Neuroimmunology external quality assessment scheme. Clin Chem Lab Med **56(11)**: 1921-1925
DOI: [10.1515/cclm-2018-0234](https://doi.org/10.1515/cclm-2018-0234)

Legast G M et al., 2017: Guillain-Barré and Miller Fisher Overlap Syndrome Mimicking Alimentary Botulism. J Clin Neurol **13(4)**: 442-443
DOI: [10.3988/jcn.2017.13.4.442](https://doi.org/10.3988/jcn.2017.13.4.442)

Han T H et al., 2017: Transient Lower Bulbar Palsy with Elevated Serum anti-GM1 and Anti-GD1b Antibodies during Aripiprazole Treatment. Pediatr Neurol **66**: 96-99
DOI: [10.1016/j.pediatrneurol.2016.07.011](https://doi.org/10.1016/j.pediatrneurol.2016.07.011)

Herrendorff R et al., 2017: Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS May 2, 2017 **114(18)**: E3689-E3698
DOI: [10.1073/pnas.1619386114](https://doi.org/10.1073/pnas.1619386114)

Anaya J-M et al., 2017: A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia. Journal of Autoimmunity **77**: 123-138
DOI: [10.1016/j.jaut.2016.12.007](https://doi.org/10.1016/j.jaut.2016.12.007)

Spatola M et al., 2016: Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes. Neurology **86**: 1780-1784
DOI: [10.1212/WNL.0000000000002558](https://doi.org/10.1212/WNL.0000000000002558)

Cao-Lormeau V M et al., 2016: Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. *Lancet* **387** (10027): 1531-1539 (incl. supplement)
DOI: [10.1016/S0140-6736\(16\)00562-6](https://doi.org/10.1016/S0140-6736(16)00562-6)

Kollewe K et al., 2015: Anti-Ganglioside Antibodies in Amyotrophic Lateral Sclerosis Revisited. *PLoS One*, **10(4)**: e0125339
DOI: [10.1371/journal.pone.0125339](https://doi.org/10.1371/journal.pone.0125339)

Posters:

Delmont E et al., 2017: Value of anti-HNK-1 Antibodies in anti-MAG Neuropathies: an analysis of 144 sera. Poster presented at **2017** "Peripheral Nerve Society" (PNS) Annual Meeting in Sitges (ES)

Chalah M A et al., 2016: A comparison of four commercial tests for detecting anti-ganglioside antibodies in patients with well-characterized dysimmune peripheral neuropathies. Poster presented at "International Congress on Autoimmunity", Leipzig (GE)

Mani B et al., 2010: The Frequency of anti-Ganglioside Antibodies in Blood Donors Compared to Control Groups and Guillain-Barré Syndrome Patients. Poster presented at "10th Dresden Symposium on Autoantibodies", Dresden (GE)

Wurster U et al., 2009: Ganglioside Antibodies in Amyotrophic Lateral Sclerosis. Poster presented at "9th Dresden Symposium on Autoantibodies", Dresden (GE)

Further literature citing anti-Ganglioside Autoantibody ELISA IVD tests by BÜHLMANN:

Kenina V et al., 2015: Clinical Impact and Relevance of Antiganglioside Antibodies Test Results. *Proc. Latvian Acad. Sci., Section B*, **69(5)**: 223-227
DOI: [10.1515/prolas-2015-0033](https://doi.org/10.1515/prolas-2015-0033)

Uysalol M et al., 2013: A Rare Form of Guillain-Barré Syndrome: A Child Diagnosed with Anti-GD1a and Anti-GD1b Positive Pharyngeal-Cervical-Brachial Variant. *Balkan Med J* **30**: 337-341
DOI: [10.5152/balkanmedj.2013.8334](https://doi.org/10.5152/balkanmedj.2013.8334)

Lei T et al., 2012: Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus. *Vaccine* **30**: 2605-2610
DOI: [10.1016/j.vaccine.2012.02.009](https://doi.org/10.1016/j.vaccine.2012.02.009)

Sharma M B et al., 2011: The presence of *Mycoplasma pneumoniae* infection and GM1 ganglioside antibodies in Guillain-Barré syndrome. *J Infect Dev Countries* **5(6)**: 459-464
DOI: [10.3855/jidc.1508](https://doi.org/10.3855/jidc.1508)

anti-MAG Autoantibodies ELISA IVD test by BÜHLMANN

Aliu B et al., 2020: Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen-specific glycopolymer; *Journal of Neurochemistry (JNC)* **154**: 486-501.
DOI: [10.1111/jnc.15021](https://doi.org/10.1111/jnc.15021) PMID: **32270492**

Liberatore G et al., 2020: Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy. *J Neuroimmunol* **345**:577288.
DOI: [10.1016/j.jneuroim.2020.577288](https://doi.org/10.1016/j.jneuroim.2020.577288) PMID: **32544754**

Neil J et al., 2020: Native vs deglycosylated IgM anti-MAG neuropathy: Correlation with clinical status – Study of 10 cases. *J Neuroimmunol.* **15**;339:577094.
DOI: [10.1016/j.jneuroim.2019.577094](https://doi.org/10.1016/j.jneuroim.2019.577094) PMID: **31756640**

Gastaldi M et al., 2020: Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. *Front Neurol.* 10:138510(1385): 1-12
PMCID: [PMC6971200](https://pubmed.ncbi.nlm.nih.gov/32010046/)

Castellani F et al., 2020: The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. *Neurol Neuroimmunol Neuroinflamm* 13;7(4):e720
DOI: [10.1212/NXI.0000000000000720](https://doi.org/10.1212/NXI.0000000000000720) PMID: **32010046** PMCID: PMC6971200

Boscarino M et al., 2020: Spinal Cord Impairment in anti-MAG Neuropathy: Evidence from Somato-sensory Evoked Potentials. *Brain Sci.* **10(282)**: 1-10
DOI: [10.3390/brainsci10050282](https://doi.org/10.3390/brainsci10050282)

Colchester N T H et al., 2020: Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes. *Haematologica* **2020** [Epub ahead of print]
DOI: [10.3324/haematol.2019.243139](https://doi.org/10.3324/haematol.2019.243139)

Pascual-Goñi E et al., 2019: Clinical and laboratory features of anti-MASG neuropathy without monoclonal gammopathy. *Sci Rep* **16**; 9(1): 6155
DOI: [10.1038/s41598-019-42545-8](https://doi.org/10.1038/s41598-019-42545-8)

Matà S et al., 2019: Anti-MAG IgM: differences in antibody tests and correlation with clinical findings. *Neurol Sci* **41(2)**: 365-372
DOI: [10.1007/s10072-019-04089-7](https://doi.org/10.1007/s10072-019-04089-7)

Svahn J et al., 2018: Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. *J Neurol Neurosurg Psychiatry* **89(5)**: 499-505
DOI: [10.1136/jnnp-2017-316715](https://doi.org/10.1136/jnnp-2017-316715)

Garg N et al., 2018: Anti-MAG neuropathy: role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. *Clin Neurophysiol* **129(10)**: 2162-2169
DOI: [10.1016/j.clinph.2018.07.021](https://doi.org/10.1016/j.clinph.2018.07.021)

Briani C et al., 2018: Obinuzumab, a new anti-CD20 antibody, and Chlorambucil are active and effective in anti-MAG antibody polyneuropathy. *Eur J Neurol* **26(2)**: 371-375
DOI: [10.1111/ene.13838](https://doi.org/10.1111/ene.13838)

Falzone YM et al., 2018: Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies; *J Neurol.* **265(12)**: 2927-2933
DOI: [10.1007/s00415-018-9081-7](https://doi.org/10.1007/s00415-018-9081-7)

D'Sa S et al., 2017: Investigation and Management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. *Brit J Haematol* **176(5)**: 728-742
DOI: [10.1111/bjh.14492](https://doi.org/10.1111/bjh.14492)

Campagnolo M et al., 2017: IgM MGUS and Waldenström-associated anti-MAG neuropathies display similar response to rituximab therapy. *J Neurol Neurosurg Psychiatry* **88(12)**: 1094-1097
DOI: [10.1136/jnnp-2017-315736](https://doi.org/10.1136/jnnp-2017-315736)

Nobile-Orazio E et al., 2017: Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan. *Expert Review of Neurotherapeutics* **17(8)**: 755-765.
DOI: [10.1080/14737175.2017.1340832](https://doi.org/10.1080/14737175.2017.1340832)

Lozeron P et al., 2016: Is distal motor/or sensory demyelination a distinctive feature of anti-MAG neuropathy? *J. Neurol* **263**: 1761-1770
DOI: [10.1007/s00415-016-8187-z](https://doi.org/10.1007/s00415-016-8187-z)

Magy L *et al.*, 2015: Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies.
J Immunol Res; **2015**: 450391
DOI: [10.1155/2015/450391](https://doi.org/10.1155/2015/450391)

Stork A C J *et al.*, 2014: Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy. J Neuroimmunol **268(1-2)**: 89-94
DOI: [10.1016/j.jneuroim.2014.01.012](https://doi.org/10.1016/j.jneuroim.2014.01.012)

Willison H J *et al.*, 2011: Use of antibody testing in nervous system disorders.
European Handbook of Neurological Management: volume 1, 2nd edition; chapter **6**: 75-80
DOI: [10.1002/9781444328394.ch6](https://doi.org/10.1002/9781444328394.ch6)

Kuijf M *et al.*, 2009: Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology **73(9)**: 688-695
DOI: [10.1212/WNL.0b013e3181b59a80](https://doi.org/10.1212/WNL.0b013e3181b59a80)

Renaud S *et al.*, 2003: Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.
Muscle Nerve **27(5)**: 611-615.
DOI: [10.1002/mus.10359](https://doi.org/10.1002/mus.10359)

Posters:

Castellani F *et al.*, 2019: Ibrutinib in Neuropathy with anti-Myelin-Associated Glycoprotein (MAG) Antibody.
Poster presented at **2019** "Peripheral Nerve Society" (PNS) Annual Meeting in Genova (IT)

Grecu N *et al.*, 2019: Small Fiber involvement in anti-MAG demyelinating neuropathy – data from a small cohort.
Poster presented at **2019** "Peripheral Nerve Society" (PNS) Annual Meeting in Genova (IT)

Herrendorff R *et al.*, 2018: Novel treatment opportunity for anti-myelin-associated glycoprotein neuropathy.
Poster presented at **2018** "Peripheral Nerve Society" (PNS) Annual Meeting in Baltimore, MY (USA)

Delmont E *et al.*, 2017: Value of anti-HNK-1 Antibodies in anti-MAG Neuropathies: an analysis of 144 sera.
Poster presented at **2017** "Peripheral Nerve Society" (PNS) Annual Meeting in Sitges (ES)

Camdessanché JP *et al.*, 2017: Therapeutic Management in 202 Patients.
Poster presented at **2017** "Peripheral Nerve Society" (PNS) Annual Meeting in Sitges (ES)

Neil J *et al.*, 2017: Do anti-MAG titers have a good correlation with clinical status in IgM anti-MAG Neuropathy?
Poster presented at **2017** "Peripheral Nerve Society" (PNS) Annual Meeting in Sitges (ES)

Further literature citing anti-MAG Autoantibodies ELISA IVD test by BÜHLMANN:

Herrendorff R *et al.*, 2017: Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigenspecific treatment option for anti-MAG neuropathy. PNAS May 2, 2017 **114(18)**: E3689-E3698
DOI: [10.1073/pnas.1619386114](https://doi.org/10.1073/pnas.1619386114)

Baron M *et al.*, 2017: Plasma exchanges for acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy. Journal of Neurology **264(6)**: 1132-1135
DOI: [10.1007/s00415-017-8502-3](https://doi.org/10.1007/s00415-017-8502-3)

Doneddu P E *et al.*, 2017: Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy (Letter to the Editor). Journal of the Neurological Sciences **373**: 344-345
DOI: [10.1016/j.jns.2016.12.029](https://doi.org/10.1016/j.jns.2016.12.029)

Gesquière-Dando A *et al.*, 2017: Are electrophysiological features related to disability in patients with anti-MAG neuropathy? Clinical Neurophysiology **47**: 75-81
DOI: [10.1016/j.neucli.2017.01.002](https://doi.org/10.1016/j.neucli.2017.01.002)

Gazzola S et al., 2017: Predictive factors of efficacy of rituximab in patients anti-MAG neuropathy. *Journal of the Neurological Sciences* **377**: 144-148
DOI: [10.1016/j.jns.2017.04.015](https://doi.org/10.1016/j.jns.2017.04.015)

Fatehi F et al., 2017: Motor unit number index (MUNIX) in patients with anti-MAG neuropathy. *Clinical Neurophysiology* **128(7)**: 1264-1269
DOI: [10.1016/j.clinph.2017.04.022](https://doi.org/10.1016/j.clinph.2017.04.022)

Campagnolo M et al., 2017: IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. *J Neurol Neurosurg Psychiatry* **88(12)**: 1094-1097
DOI: [10.1136/jnnp-2017-315736](https://doi.org/10.1136/jnnp-2017-315736)

Gomez A and Hoffman J E, 2016: Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy with Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ : Case Report and Review of the Literature. *Clin Lymphoma Myeloma Leuk* **16(7)**: e101-108.
DOI: [10.1016/j.clml.2016.04.004](https://doi.org/10.1016/j.clml.2016.04.004)

Stork A C J et al., 2016: Classical and lectin complement pathway activity in polyneuropathy associated with IgM monoclonal gammopathy. *J Neuroimmunol* **290**: 76-79
DOI: [10.1016/j.jneuroim.2015.11.010](https://doi.org/10.1016/j.jneuroim.2015.11.010)

Ferfaglia R I et al., 2016: Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. *J Peripher Nerv Syst* **21(1)**: 10-14
DOI: [10.1111/jns.12156](https://doi.org/10.1111/jns.12156)

Campagnolo M et al., 2015: Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment. *J Neuroimmunol* **281**: 1-4
DOI: [10.1016/j.jneuroim.2015.02.009](https://doi.org/10.1016/j.jneuroim.2015.02.009)

Stork A C J et al., 2014: Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature. *J Neurol* **261(7)**: 1389-1404
DOI: [10.1007/s00415-014-7354-3](https://doi.org/10.1007/s00415-014-7354-3)

Sala E et al., 2014: Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy. *J Neurol Sci* **345(1-2)**: 224-227
DOI: [10.1016/j.jns.2014.07.055](https://doi.org/10.1016/j.jns.2014.07.055)

Bridel C et al., 2014: Multifocal motor neuropathy with high titers of anti-MAG antibodies. *J Peripher Nerv Syst* **19(2)**: 180-182
DOI: [10.1111/jns5.12069](https://doi.org/10.1111/jns5.12069)

Hospital M A et al., 2013: Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. *Haematologica* **98(12)**: e155-157
DOI: [10.3324/haematol.2013.087213](https://doi.org/10.3324/haematol.2013.087213)

Piscosquito G et al., 2013: Coexistence of Charcot-Marie-Tooth disease type 1A and anti-MAG neuropathy. *J Peripher Nerv Syst* **18(2)**: 185-188
DOI: [10.1111/jns5.12029](https://doi.org/10.1111/jns5.12029)

Stork A C J et al., 2013: Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment. *J Peripher Nerv Syst* **18(2)**: 189-192
DOI: [10.1111/jns5.12018](https://doi.org/10.1111/jns5.12018)

Pihan M et al., 2012: [Neuropathies associated with monoclonal IgM anti-MAG antibodies]. *Rev Med Interne* **33(12)**: 686-692
DOI: [10.1016/j.revmed.2012.05.009](https://doi.org/10.1016/j.revmed.2012.05.009)

Maurer M A et al., 2012: Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. *J Clin Invest* **122(4)**:1393-1402
DOI: [10.1172/JCI58743](https://doi.org/10.1172/JCI58743)

Mostafa G A et al., 2012: Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. *J Neuroinflammation* **17(9)**: 201
DOI: [10.1186/1742-2094-9-201](https://doi.org/10.1186/1742-2094-9-201)

Zara G et al., 2011: Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy. *Clin Neurophysiol* **122(12)**: 2518-2522
DOI: [10.1016/j.clinph.2011.05.015](https://doi.org/10.1016/j.clinph.2011.05.015)

Matà S et al., 2011: Anti-myelin associated glycoprotein antibodies recognize HNK-1 epitope on CNS. *J Neuroimmunol* **236(1-2)**: 99-105
DOI: [10.1016/j.jneuroim.2011.05.002](https://doi.org/10.1016/j.jneuroim.2011.05.002)

Larue S et al., 2011: Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. *Eur J Neurol* **18(6)**: 899-905
DOI: [10.1111/j.1468-1331.2010.03312.x](https://doi.org/10.1111/j.1468-1331.2010.03312.x)

Matà S et al., 2011: IgM monoclonal gammopathy-associated neuropathies with different IgM specificity. *Eur J Neurol* **18(8)**: 1067-1073
DOI: [10.1111/j.1468-1331.2010.03345.x](https://doi.org/10.1111/j.1468-1331.2010.03345.x)

Jurici S et al., 2011: An Autopsy Case of Amyotrophic Lateral Sclerosis with Waldenstrom Macroglobulinemia and Anti-MAG Gammopathy. *Case Rep Neurol* **3(3)**: 294-400
DOI: [10.1159/000335004](https://doi.org/10.1159/000335004)

Gruson B et al., 2011: Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. *J Peripher Nerv Syst* **16(3)**: 180-185
DOI: [10.1111/j.1529-8027.2011.00343.x](https://doi.org/10.1111/j.1529-8027.2011.00343.x)

Théaudin M et al., 2011: Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study. *Rev Neurol (Paris)* **167(12)**: 897-904
DOI: [10.1016/j.neurol.2011.04.005](https://doi.org/10.1016/j.neurol.2011.04.005)

Delmont E et al., 2011: Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies. *J Neurol* **258(9)**: 1717-1719
DOI: [10.1007/s00415-011-5994-0](https://doi.org/10.1007/s00415-011-5994-0)

Jaskowsky T D et al., 2007: Further comparisons of assays for detecting MAG IgM autoantibodies. *J Neuroimmunol* **187(1-2)**: 175-178
DOI: [10.1016/j.jneuroim.2007.04.015](https://doi.org/10.1016/j.jneuroim.2007.04.015)

Steck A et al., 2006: Anti-myelin-associated glycoprotein neuropathy. *Curr Opin Neurol* **19(5)**: 458-463
DOI: [10.1097/01.wco.0000245368.36576.0d](https://doi.org/10.1097/01.wco.0000245368.36576.0d)

Renaud S et al., 2006: High-dose rituximab and anti-MAG-associated polyneuropathy. *Neurology* **66(5)**: 742-744
DOI: [10.1212/01.wnl.0000201193.00382.b3](https://doi.org/10.1212/01.wnl.0000201193.00382.b3)

Caudie C et al., 2006: [Diagnostic value of autoantibodies to MAG by ELISA Bühlmann in 117 immune-mediated peripheral neuropathies associated with monoclonal IgM to SGPG/SGLPG]. *Ann Biol Clin* **64(4)**: 353-359
PMID: [16829480](https://pubmed.ncbi.nlm.nih.gov/16829480/)

Kvarnström M et al., 2002: Myelin protein P0-specific IgM producing monoclonal B cell lines were established from polyneuropathy patients with monoclonal gammopathy of undetermined significance (MGUS). *Clin Exp Immunol* **127(2)**: 255-262
DOI: [10.1046/j.1365-2249.2002.01739.x](https://doi.org/10.1046/j.1365-2249.2002.01739.x)

anti-SGPG Autoantibodies ELISA IVD test by BÜHLMANN

Herrendorff R et al., 2017: Selective *in vivo* removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS May 2, 2017 **114(18)**: E3689-E3698
DOI: [10.1073/pnas.1619386114](https://doi.org/10.1073/pnas.1619386114)

Caudie C et al., 2007: [Diagnostic value of the anti-IgM SGPG Elisa (BÜHLMANN Laboratories AG) in 147 sera with a monoclonal IgM anti-MAG/SGPG antibody-associated neuropathy]. Ann Biol Clin (Paris) **65(4)**: 369-375
PMID: [17627917](https://pubmed.ncbi.nlm.nih.gov/17627917/)

Bridel C et al., 2014: Multifocal motor neuropathy with high titres of anti-MAG antibodies.
J Peripher Nerv Syst **19(2)**: 180-182
DOI: [10.1111/jns5.12069](https://doi.org/10.1111/jns5.12069)

Kuijf M et al., 2009: Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology **73(9)**: 688-695
DOI: [10.1212/WNL.0b013e3181b59a80](https://doi.org/10.1212/WNL.0b013e3181b59a80)